How can a researcher improve their IRB application when patient notification of cervical cancer screening results is a concern?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IRB Application Approval for Cervical Cancer Screening Research

The researcher must send reports to ALL patients (both positive and negative results) to gain IRB approval, making option B the correct answer. This is a fundamental ethical requirement for research involving cervical cancer screening.

Ethical Requirements for Return of Research Results

The core issue preventing IRB approval is the failure to notify participants of their screening results. This violates multiple ethical principles:

  • The CDC guidelines explicitly state that positive cervical cancer screening results require immediate notification because appropriate follow-up is essential to prevent progression to invasive cancer 1
  • A written plan with a timeline for returning ALL results to participants must be developed during the research design phase and incorporated into the study protocol, as recommended by the NIH 1
  • The plan must capture "alert" values (positive results) that should be reported immediately to individuals, according to ACOG 1

Why Partial Notification Is Insufficient

Options C and D (notifying only negative cases or only positive cases) are inadequate:

  • Providers must communicate the meaning of BOTH cytology and HPV test results directly to patients, as stated by the CDC 1
  • The consent form must explicitly state that positive screening results will be communicated directly to participants, along with the approximate timeline for receiving results and where to seek follow-up care 1
  • Withholding negative results denies patients important health information and violates the principle of respect for persons 2

Required Protocol Elements for IRB Approval

To gain approval, the researcher must specify:

  • Method of contact and backup contact method for result notification 1
  • Specific referral locations or providers for follow-up care 1
  • Timeline for result notification 1
  • Documentation procedures to confirm participants received and understood their results 1

Common Pitfall to Avoid

The researcher cannot assume that simply calling positive cases (option D) satisfies ethical obligations. Both positive AND negative results must be communicated to maintain transparency and respect participant autonomy 1. Failing to notify negative cases leaves participants uncertain about their health status and undermines informed consent.

Clinical Context

This requirement is particularly critical because:

  • Abnormal screening results can cause short-term anxiety, including concerns about sexually transmitted infections, requiring proper counseling 2
  • Cervical cancer screening has proven effectiveness in reducing incidence and mortality through early detection and treatment of precancerous lesions 2
  • Unscreened women account for more than half of cervical cancer cases, making proper follow-up essential 2

References

Guideline

Cervical Cancer Screening Research Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.